u/Old_Lavishness_4341

Summer 2027 Consulting Internship or 2027 FT Role

Did anyone hear back? I did my final round earlier this week but haven't heard back yet. People I've talked to from the previous year mentioned that a verbal offer should be given within the same week. Idk if I should just accept my fate or not at this point.

Hey everyone,

I’ve been diving into AstraZeneca ($AZN) recently and noticed it rarely gets mentioned here. Despite being a massive pharma player, its daily retail trading volume feels surprisingly quiet.

On paper, the long-term thesis looks incredibly strong. Management is targeting $80 billion in revenue by 2030, backed by a massive oncology and rare disease pipeline. Relative to hyper-growth peers like Eli Lilly, AZN trades at a much more reasonable valuation (PEG ratio around 1.3–1.5), making it look like a classic "Growth at a Reasonable Price" (GARP) play.

However, the stock has faced a notable pullback recently, and I'm trying to weigh the near-term risks against that 2030 target:

• The Patent Cliff: Blockbuster drugs like Farxiga are facing an upcoming loss of exclusivity.
• Pipeline Speedbumps: We've seen some recent FDA delays and pipeline setbacks (like camizestrant) that seem to have cooled off institutional momentum.
• Geopolitical Noise: Ongoing regulatory scrutiny surrounding their China operations continues to hang over the stock.

For those who hold or follow AZN: Do you view this recent dip as a solid accumulation window for a defensive growth stock? Or do you think the pipeline bottlenecks and patent losses will make hitting that $80B target a massive uphill battle?

Would love to get your insights on how you're playing this.